there seems to be some heavy resistance around these level with a lot of potential upside.

Ok thanks - obviously conflicting data!

From the Digital page, it seems there may have been a JPM forecast
after 17 June as well, as the TP is given as unchanged from the previous 1446p TP
given there.

On the LSE site, it shows your figure yesterday, but shows no other JPM update going back til 18th July - so if there was a TP price change, it must have been between 17th June and 17th July.

Anyway a tad frustrating.

Sept 15: Deutsche: Hold - Reduces TP from 1500p to 1450p.

Ebola news

Skin cancer drug deal

GSK China Investigation Outcome

GlaxoSmithKline plc (GSK) today announced that the Changsha Intermediate People's Court in Hunan Province, China ruled that GSK China Investment Co. Ltd (GSKCI) has, according to Chinese law, offered money or property to non-government personnel in order to obtain improper commercial gains, and been found guilty of bribing non-government personnel. The verdict follows investigations initiated by China's Ministry of Public Security in June 2013.

As a result of the Court's verdict, GSKCI will pay a fine of £297 million (3 billion RMB at a currency exchange rate of 10.0980) to the Chinese government. This will be funded through existing cash resources. Associated costs and charges related to restructuring will be included in GSK's third quarter update.

The illegal activities of GSKCI are a clear breach of GSK's governance and compliance procedures; and are wholly contrary to the values and standards expected from GSK employees. GSK has published a statement of apology to the Chinese government and its people on its website (www.gsk-china.com).

GSK has co-operated fully with the authorities and has taken steps to comprehensively rectify the issues identified at the operations of GSKCI. This includes fundamentally changing the incentive program for its salesforces (decoupling sales targets from compensation); significantly reducing and changing engagement activities with healthcare professionals; and expanding processes for review and monitoring of invoicing and payments.

Ex-head to be deported not jailed

Sept 22: Goldman Sachs: Buy - TP: 1670p

Sept 20: Questor/Telegraph

China fallout and CEO

Sept 23: Credit Suisse: Underperform - TP: 1400p

Directorate Change

GlaxoSmithKline plc appoints Sir Philip Hampton to the Board of Directors

Sept 30:
Jefferies and Deutsche: Hold - TP; N/A
Numis: Hold - TP: 1600p

Oct 7: Deutsche keeps Hold but reduces TP from 1450p to 1420p.

Late news yesterday: GSK: UAE investigation

GSK/Ebola

Anyone recommend a good price to get in? Looking very tempting at these levels.

3rd Quarter Results

Summary
· Group turnover £5.6 billion, -3% excluding divestments

- Pharmaceutical and Vaccines sales -3% with strong growth in Emerging Markets, +12%, Japan +6%, ViiV Healthcare +18%, offset by US -10%, and Europe -2%

- Respiratory -8% reflecting significant changes to pricing and volumes for Advair in US; portfolio transition continues with total global respiratory sales expected to return to growth in 2016

- Q3 Consumer Healthcare sales -3%; recovery from supply interruptions on track with full year sales expected to be broadly flat subject to continued progress of supply recovery plan

· Targeted cost reductions and financial efficiencies help deliver Q3 core EPS of 27.9p +5% at CER and excluding divestments

· Continue to expect full year 2014 core EPS to be broadly similar to 2013 (at CER and on ex-divestment basis)

· Proposed 3-part transaction with Novartis on track for completion in H1 2015

- Will significantly strengthen Vaccines and Consumer Healthcare

- New balance for Group across core businesses of Pharmaceuticals, Vaccines and Consumer Healthcare

- Provides greater ability to create and deliver value for shareholders across the Group

· ViiV Healthcare: intention to explore an IPO of a minority shareholding to enhance future strategic flexibility and visibility within the Group

· New restructuring programme to refocus global pharmaceuticals business and cost base following divestment of oncology products and changed US respiratory market dynamics

- Approximately £1 billion annual cost savings to be delivered over 3 years with ~50% expected in 2016. Savings incremental to the existing announced programmes and additional to the benefits expected from the transaction

· R&D pipeline expected to fuel growth of pharmaceuticals business with sustained flow of new products over next 5-10 years

- Multiple phase II/III assets with significant potential, including: mepolizumab (severe asthma), sirukumab (RA), cabotegravir (HIV); losmapimod (ACS); ICS/LAMA/LABA (COPD); '863 (anaemia); '273 (ADA-SCID)

- Early clinical development opportunities include first-in-class molecules in epigenetics targeting oncology and immuno-inflammation (BETi, EZH2 and LSD-1); respiratory (PI3Kδ); cardiovascular diseases (TRPV4) and inflammatory diseases (RIP-1 & 2 kinases)

· Q3 dividend maintained at 19p per share

· FY14 dividend expected to be 80p +3%. 2015 dividend expected to be maintained at same level as 2014 with additional planned return of £4 billion to shareholders via a B-share scheme post completion of transaction

Some encouraging signs in today's statement imo.

Oct 22; Panmure Gordon: Hold - TP: down to 1425p from 1600 on 30 Sept.

This being a core high yield holding for me, I tend to look at low sp as an opportunity to add
and think recent sp under 1330, often well under that, was favourable, if holding for the long term.

#GlaxoSmithKline advises that its #ebola vaccine should be ready by the close of the year.